| Ident. | Authors (with country if any) | Title |
|---|
| 001143 (2012) |
Bruno Dubois [France] ; Eduardo Tolosa [Espagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Gunther Schumann [Allemagne] ; Emmanuelle Pourcher [Canada] ; Julian Gray [Suisse] ; Gail Thomas [Royaume-Uni] ; Jina Swartz [Royaume-Uni] ; Timothy Hsu [États-Unis] ; Margaret L. Moline [États-Unis] | Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study |
| 001331 (2011) |
Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit [Turquie] ; P Nar Unsalan [Turquie] ; Hilal Horozoglu [Turquie] ; Nese Tuncer [Turquie] ; Aynur Feyzioglu [Turquie] ; Dilek Ince Gunal [Turquie] ; Gorsev G. Yener [Turquie] ; Raif Cakmur [Turquie] ; Huseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study |
| 001397 (2011) |
Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni] ; the RECOVER Study Group [Allemagne, Afrique du Sud, Pologne, Hongrie, États-Unis, Nouvelle-Zélande, Finlande, Royaume-Uni, Italie, Espagne, Autriche] | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) |
| 001590 (2011) |
Helge Hellriegel [Allemagne] ; Jan Raethjen [Allemagne] ; G. Deuschl [Allemagne] ; Jens Volkmann [Allemagne] | Levetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study |
| 001783 (2011) |
Arianna Guidubaldi [Italie] ; Alfonso Fasano [Italie] ; Tamara Ialongo [Italie] ; Carla Piano [Italie] ; Maurizio Pompili [Italie] ; Roberta Mascianà [Italie] ; Luisa Siciliani [Italie] ; Mario Sabatelli [Italie] ; Anna Rita Bentivoglio [Italie] | Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double‐blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease |
| 001958 (2010) |
Endre Pal [Hongrie] ; Ferenc Nagy [Hongrie] ; Zsuzsanna Aschermann [Hongrie] ; Eva Balazs [Hongrie] ; Norbert Kovacs [Hongrie] | The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double‐blind, placebo‐controlled study |
| 001B37 (2010) |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
| 001D33 (2010) |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
| 001E90 (2010) |
Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande] | A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease |
| 002073 (2009) |
Gottfried Kranz [Autriche] ; Dietrich Haubenberger [Autriche] ; Bernhard Voller [Autriche] ; Martin Posch [Autriche] ; Peter Schnider [Autriche] ; Eduard Auff [Autriche] ; Thomas Sycha [Autriche] | Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study |
| 002932 (2008) |
David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France] | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study |
| 002B37 (2007) |
Tanya Gurevich [Israël] ; Chava Peretz [Israël] ; Orna Moore [Israël] ; Nina Weizmann [Israël] ; Nir Giladi [Israël] | The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study |
| 002B91 (2007) |
Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France] | Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study |
| 002B93 (2007) |
Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole |
| 002C71 (2007) |
Yoshikuni Mizuno [Japon] ; Ichiro Kanazawa [Japon] ; Sadako Kuno [Japon] ; Nobuo Yanagisawa [Japon] ; Mitsutoshi Yamamoto [Japon] ; Tomoyoshi Kondo [Japon] | Placebo‐controlled, double‐blind dose‐finding study of entacapone in fluctuating parkinsonian patients |
| 002E64 (2007) |
Wolfgang H. Oertel [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Bettina Bergtholdt [Allemagne] ; Yngve Hallström [Suède] ; Jaan Albo [Suède] ; Lena Leissner [Suède] ; Thomas Schindler [Allemagne] ; Juergen Koester [Allemagne] ; Juergen Reess [Allemagne] | Efficacy of pramipexole in restless legs syndrome: A six‐week, multicenter, randomized, double‐blind study (effect‐RLS study) |
| 002E71 (2007) |
Jose M. Rabey [Israël] ; Tatiana Prokhorov [Israël] ; Ala Miniovitz [Israël] ; Eugenia Dobronevsky [Israël] ; Colin Klein [Israël] | Effect of quetiapine in psychotic Parkinson's disease patients: A double‐blind labeled study of 3 months' duration |
| 003031 (2007) |
Jaime Kulisevsky [Espagne] ; Berta Pascual-Sedano [Espagne] ; Manel Barbanoj [Espagne] ; Alexandre Gironell [Espagne] ; Javier Pagonabarraga [Espagne] ; Carmen García-Sánchez [Espagne] | Acute effects of immediate and controlled‐release levodopa on mood in Parkinson's disease: A double‐blind study |
| 003450 (2006) |
Alexei Korchounov [Allemagne, Égypte] ; Gregory Bogomazov [Russie] | Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double‐blind, randomized, placebo‐controlled study of entacapone adjunctive therapy |
| 003555 (2006) |
Giovanni Lagalla [Italie] ; Marzia Millevolte [Italie] ; Marianna Capecci [Italie] ; Leandro Provinciali [Italie] ; Maria Gabriella Ceravolo [Italie] | Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study |
| 003623 (2006) |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease |
